Published Date: 06 Jul 2026
But the remote intervention showed signals of benefit over the longer term and in subgroups
Read Full NewsAt CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.
At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.
Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.
Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD
TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation